Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2011, Article ID 957957, 9 pages
http://dx.doi.org/10.1155/2011/957957
Review Article

Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions

Division of Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, MLC 7015, 3333 Burnet Avenue, Cincinnati, OH 45229, USA

Received 1 July 2010; Accepted 17 January 2011

Academic Editor: Irene Andrulis

Copyright © 2011 Lars Wagner. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. B. Womer, D. C. West, M. D. Krailo, P. S. Dickman, and B. Pawel, “Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT),” Journal of Clinical Oncology, vol. 26, no. 15, 2008, abstract no. 10504. View at Google Scholar
  2. A. G. Shankar, S. Ashley, A. W. Craft, and C. R. Pinkerton, “Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma,” Medical and Pediatric Oncology, vol. 40, no. 3, pp. 141–147, 2003. View at Publisher · View at Google Scholar · View at PubMed
  3. B. H. Kushner and P. A. Meyers, “How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 870–880, 2001. View at Google Scholar · View at Scopus
  4. H. E. Grier, M. D. Krailo, N. J. Tarbell et al., “Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone,” New England Journal of Medicine, vol. 348, no. 8, pp. 694–701, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. L. Granowetter, R. Womer, M. Devidas et al., “Dose-intensified compared with standard chemotherapy for nonmetastatic ewing sarcoma family of tumors: a Children's Oncology Group study,” Journal of Clinical Oncology, vol. 27, no. 15, pp. 2536–2541, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. P. J. Houghton, C. F. Stewart, P. J. Cheshire et al., “Antitumor activity of temozolomide combined with irinotecan is partly independent of O-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models,” Clinical Cancer Research, vol. 6, no. 10, pp. 4110–4118, 2000. View at Google Scholar · View at Scopus
  7. P. Pourquier, J. L. Waltman, Y. Urasaki et al., “Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine,” Cancer Research, vol. 61, no. 1, pp. 53–58, 2001. View at Google Scholar · View at Scopus
  8. P. J. Houghton, P. J. Cheshire, J. D. Hallman II et al., “Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at IOW dose levels in protracted schedules to mice bearing xenografts of human tumors,” Cancer Chemotherapy and Pharmacology, vol. 36, no. 5, pp. 393–403, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. Blaney, M. N. Needle, A. Gillespie et al., “Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: a collaborative pediatric branch, national cancer institute, and Children's Cancer Group study,” Clinical Cancer Research, vol. 4, no. 2, pp. 357–360, 1998. View at Google Scholar · View at Scopus
  10. D. S. Hawkins, S. Bradfield, J. A. Whitlock et al., “Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study,” Pediatric Blood and Cancer, vol. 47, no. 6, pp. 790–794, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. D. Desai, T. K. Li, A. Rodriguez-Bauman, E. H. Rubin, and L. F. Liu, “Ubiquitin/26s proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells,” Cancer Research, vol. 61, no. 15, pp. 5926–5932, 2001. View at Google Scholar · View at Scopus
  12. M. L. Bernstein, M. Devidas, D. Lafreniere et al., “Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—a report from the Children's Oncology Group,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 152–159, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. R. L. Saylors III, K. C. Stine, J. Sullivan et al., “Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group phase II study,” Journal of Clinical Oncology, vol. 19, no. 15, pp. 3463–3469, 2001. View at Google Scholar
  14. A. Hunold, N. Weddeling, M. Paulussen, A. Ranft, C. Liebscher, and H. Jürgens, “Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors,” Pediatric Blood and Cancer, vol. 47, no. 6, pp. 795–800, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. V. M. Santana, W. L. Furman, C. A. Billups et al., “Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4039–4047, 2005. View at Publisher · View at Google Scholar · View at PubMed
  16. P. Schaiquevich, J. C. Panetta, L. C. Iacono et al., “Population pharmacokinetic analysis of topotecan in pediatric cancer patients,” Clinical Cancer Research, vol. 13, no. 22, pp. 6703–6711, 2007. View at Publisher · View at Google Scholar · View at PubMed
  17. N. C. Daw, V. M. Santana, L. C. Iacono et al., “Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 829–837, 2004. View at Publisher · View at Google Scholar · View at PubMed
  18. D. C. Bowers, V. M. Aquino, P. J. Leavey et al., “Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors,” Pediatric Blood and Cancer, vol. 42, no. 1, pp. 93–98, 2004. View at Google Scholar
  19. A. Donfrancesco, M. A. De Ioris, H. P. McDowell et al., “Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response,” Pediatric Blood and Cancer, vol. 54, no. 1, pp. 55–61, 2010. View at Publisher · View at Google Scholar · View at PubMed
  20. J. R. Eckardt, J. Von Pawel, J. L. Pujol et al., “Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 2086–2092, 2007. View at Publisher · View at Google Scholar · View at PubMed
  21. H. Carol, P. J. Houghton, C. L. Morton et al., “Initial testing of topotecan by the Pediatric Preclinical Testing Program,” Pediatric Blood and Cancer, vol. 54, no. 5, pp. 707–715, 2010. View at Publisher · View at Google Scholar · View at PubMed
  22. B. H. Kushner, K. Kramer, P. A. Meyers, N. Wollner, and N. K. V. Cheung, “Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors,” Medical and Pediatric Oncology, vol. 35, no. 5, pp. 468–474, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Ferrari, A. B. Del Prever, E. Palmerini et al., “Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma,” Pediatric Blood and Cancer, vol. 52, no. 5, pp. 581–584, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. W. L. Furman, C. F. Stewart, C. A. Poquette et al., “Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1815–1824, 1999. View at Google Scholar · View at Scopus
  25. L. Mascarenhas, E. R. Lyden, P. P. Breitfeld et al., “Randomized phase II window study of two schedules of irinotecan and vincristine in rhabdomyosarcoma patients at first relapse/disease progression,” Journal of Clinical Oncology, vol. 26, p. 542s, 2008. View at Google Scholar
  26. N. E. Schoemaker, I. E. L. M. Kuppens, V. Moiseyenko et al., “A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer,” British Journal of Cancer, vol. 91, no. 8, pp. 1434–1441, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. Y. Fujiwara and H. Minami, “An overview of the recent progress in irinotecan pharmacogenetics,” Pharmacogenomics, vol. 11, no. 3, pp. 391–406, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. Camptosar Package Insert, Pfizer, Inc., New York, NY, USA, 2006.
  29. L. R. Bomgaars, M. Bernstein, M. Krailo et al., “Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study,” Journal of Clinical Oncology, vol. 25, no. 29, pp. 4622–4627, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. C. F. Stewart, J. C. Panetta, M. A. O'Shaughnessy et al., “UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan,” Journal of Clinical Oncology, vol. 25, no. 18, pp. 2594–2600, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. L. M. Wagner, J. P. Perentesis, J. M. Reid et al., “Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group Phase I consortium study,” Pediatric Blood and Cancer, vol. 54, no. 4, pp. 538–545, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. L. M. Wagner, J. G. Villahlanca, C. F. Stewart et al., “Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1290–1296, 2009. View at Publisher · View at Google Scholar · View at PubMed
  33. W. L. Furman, K. R. Crews, C. Billups et al., “Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors,” Journal of Clinical Oncology, vol. 24, no. 4, pp. 563–570, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. L. M. Wagner, “Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?” Pediatric Blood and Cancer, vol. 54, no. 5, pp. 661–662, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. L. M. Wagner, N. McAllister, R. E. Goldsby et al., “Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma,” Pediatric Blood and Cancer, vol. 48, no. 2, pp. 132–139, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. D. A. Casey, L. H. Wexler, M. S. Merchant et al., “Irinotecan and temozolomide for Ewing sarcoma: the memorial sloan-kettering experience,” Pediatric Blood and Cancer, vol. 53, no. 6, pp. 1029–1034, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. M. Cosetti, L. H. Wexler, E. Calleja et al., “Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience,” Journal of Pediatric Hematology/Oncology, vol. 24, no. 2, pp. 101–105, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Bisogno, R. Riccardi, A. Ruggiero et al., “Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma,” Cancer, vol. 106, no. 3, pp. 703–707, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. G. C. Sergio, G. M. Félix, and J. V. Luis, “Activated charcoal to prevent irinotecan-induced diarrhea in children,” Pediatric Blood and Cancer, vol. 51, no. 1, pp. 49–52, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. L. M. Wagner, K. R. Crews, C. F. Stewart et al., “Reducing irinotecan-associated diarrhea in children,” Pediatric Blood and Cancer, vol. 50, no. 2, pp. 201–207, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. A. S. Pappo, E. Lyden, P. Breitfeld et al., “Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group,” Journal of Clinical Oncology, vol. 25, no. 4, pp. 362–369, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. G. Vassal, M. J. Terrier-Lacombe, M. C. Bissery et al., “Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts,” British Journal of Cancer, vol. 74, no. 4, pp. 537–545, 1996. View at Google Scholar · View at Scopus
  43. V. J. Patel, G. B. Elion, P. J. Houghton et al., “Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft,” Clinical Cancer Research, vol. 6, no. 10, pp. 4154–4157, 2000. View at Google Scholar · View at Scopus
  44. P. Anderson, L. Kopp, N. Anderson et al., “Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma),” Expert Opinion on Investigational Drugs, vol. 17, no. 11, pp. 1703–1715, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. P. J. Houghton, P. J. Cheshire, J. C. Hallman, M. C. Bissery, A. Mathieu-Boue, and J. A. Houghton, “Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin,” Cancer Research, vol. 53, no. 12, pp. 2823–2829, 1993. View at Google Scholar · View at Scopus
  46. R. Y. McNall-Knapp, C. N. Williams, E. N. Reeves, R. L. Heideman, and W. H. Meyer, “Extended phase I evaluation of vincristine, Irinotecan, temozolomide, and antibiotic in children with refractory solid tumors,” Pediatric Blood and Cancer, vol. 54, no. 7, pp. 909–915, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. P. Van Winkle, A. Angiolillo, M. Krailo et al., “Ifosfamide, Carboplatin, and Etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience,” Pediatric Blood and Cancer, vol. 44, no. 4, pp. 338–347, 2005. View at Publisher · View at Google Scholar · View at PubMed
  48. E. A. Czyzewski, S. Goldman, A. J. Mundt, J. Nachman, C. Rubin, and D. E. Hallahan, “Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study,” International Journal of Radiation Oncology, Biology, Physics, vol. 44, no. 3, pp. 569–577, 1999. View at Publisher · View at Google Scholar
  49. R. K. Jain, “Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy,” Science, vol. 307, no. 5706, pp. 58–62, 2005. View at Publisher · View at Google Scholar · View at PubMed
  50. P. V. Dickson, J. B. Hamner, T. L. Sims et al., “Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy,” Clinical Cancer Research, vol. 13, no. 13, pp. 3942–3950, 2007. View at Publisher · View at Google Scholar · View at PubMed
  51. P. Leavey, J. L. Glade-Bender, L. Mascarenhas et al., “Feasibility of bevacizumab combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewings sarcoma: a Children’s Oncology Group study,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, abstract no. 9552. View at Google Scholar
  52. D. Olmos, D. S. W. Tan, R. L. Jones, and I. R. Judson, “Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside,” Cancer Journal, vol. 16, no. 3, pp. 183–194, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. Z. Wang, G. Chakravarty, S. Kim et al., “Growth-inhibitory effects of human anti-insulin-like growth factor-1 receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma,” Clinical Cancer Research, vol. 12, no. 15, pp. 4755–4765, 2006. View at Publisher · View at Google Scholar · View at PubMed
  54. S. Malempati, B. Weigel, A. M. Ingle et al., “A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: a Children's Oncology Group phase I consortium study,” Journal of Clinical Oncology, vol. 27, 2009, abstract no. 10013. View at Google Scholar
  55. D. Olmos, S. Postel-Vinay, L. R. Molife et al., “Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study,” The Lancet Oncology, vol. 11, no. 2, pp. 129–135, 2010. View at Publisher · View at Google Scholar
  56. C. F. Stewart, M. Leggas, J. D. Schuetz et al., “Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice,” Cancer Research, vol. 64, no. 20, pp. 7491–7499, 2004. View at Publisher · View at Google Scholar · View at PubMed
  57. S. Nagashima, H. Soda, M. Oka et al., “BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 5, pp. 594–600, 2006. View at Publisher · View at Google Scholar · View at PubMed
  58. W. L. Furman, F. Navid, N. C. Daw et al., “Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors,” Journal of Clinical Oncology, vol. 27, no. 27, pp. 4599–4604, 2009. View at Publisher · View at Google Scholar · View at PubMed
  59. A. Gupta, Y. Dai, R. R. Vethanayagam et al., “Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 3, pp. 374–383, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. E. Pencreach, E. Guérin, C. Nicolet et al., “Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-lnducible factor-1α axis,” Clinical Cancer Research, vol. 15, no. 4, pp. 1297–1307, 2009. View at Publisher · View at Google Scholar · View at PubMed
  61. P. J. Houghton, C. L. Morton, E. A. Kolb et al., “Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program,” Pediatric Blood and Cancer, vol. 50, no. 4, pp. 799–805, 2008. View at Publisher · View at Google Scholar · View at PubMed
  62. C. R. Calabrese, R. Almassy, S. Barton et al., “Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361,” Journal of the National Cancer Institute, vol. 96, no. 1, pp. 56–67, 2004. View at Google Scholar
  63. L. Tentori, C. Leonetti, M. Scarsella et al., “Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma,” The FASEB Journal, vol. 20, no. 10, pp. 1709–1711, 2006. View at Publisher · View at Google Scholar · View at PubMed
  64. Z. Guo, J. J. Wheler, A. Naing et al., “Clinical pharmacokinetics of EZN-2208, a novel anticancer agent, in patients with advanced malignancies: a phase i, first-in-human, dose-escalation study,” Journal of Clinical Oncology, vol. 26, 2008, abstract no. 2556. View at Google Scholar
  65. P. Sapra, H. Zhao, M. Mehlig et al., “Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model,” Clinical Cancer Research, vol. 14, no. 6, pp. 1888–1896, 2008. View at Publisher · View at Google Scholar · View at PubMed